ClinicalTrials.gg
CompletedNCT00888069Updated Sep 30, 2014

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

A Phase 1 interventional study of CTAP101 Capsules and CTAP101 Injection in Chronic Kidney Disease, Secondary Hyperparathyroidism and Chronic Renal Insufficiency, sponsored by OPKO IP Holdings II, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-09-30.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by OPKO IP Holdings II, Inc. (part of OPKO Health, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
402nd of 638
28 · median 48
Started
2009
with 32 others
Phase 1
89 of 765
8 open now
Registered
182nd of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 402nd largest by enrollment of the 638 interventional ones that give a count, is one of 33 that started in 2009, is one of 89 in phase 1, and was the 182nd registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

This study will investigate how the levels of a single dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with Stage 3 or 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism (SHPT).

03

Conditions studied

  • Chronic Kidney Disease
  • Secondary Hyperparathyroidism
  • Chronic Renal Insufficiency
  • Chronic Renal Failure

Keywords

  • Parathyroid Diseases
  • Renal Insufficiency
  • Kidney Failure, Chronic
  • Hyperparathyroidism, Secondary
  • Vitamin D
  • Hyperparathyroidism
  • Renal Insufficiency, Chronic
  • Kidney Diseases
  • Kidney Failure
04

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 28 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

OPKO IP Holdings II, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

First submitted before OPKO IP Holdings II, Inc. became part of OPKO Health, Inc..

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between great than or equal to 18 and less than or equal to 40 kg/m2
  • Plasma iPTH value for Stage 3 CKD greater than or equal to 70 pg/mL and lower than or equal to 1000 pg/mL
  • Plasma iPTH value for Stage 4 CKD greater than or equal to 110 pg/mL and lower than or equal to 1000 pg/mL
  • Adjusted serum total calcium value greater than 8.4 mg/dL and lower than 10.0 mg/dL
  • Serum phosphorus value greater than or equal to 2.5 mg/dL and lower than or equal to 5.5 mg/dL
  • Serum 25-hydroxyvitamin D level greater than 15 ng/mL and lower than 30 ng/mL
  • level greater than or equal to 10 g/dL

Exclusion criteria

Exclusion Criteria:

  • Has nephrotic range proteinuria
  • Has liver disease or significant hepatic dysfunction
  • Is taking Cytochrome P450 3A4 inhibitors or inducers
  • Has adult history of kidney stones and dysphagia
  • Has known history of alcohol/controlled substance abuse or are positive for drug of abuse screen
  • Currently on dialysis
  • Current serious illness such as cancer, , cardiovascular event or hepatitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Low Dose CTAP101 Capsules

    CTAP101 Capsules, 450 mcg dose

    Drug: CTAP101 Capsules

  • Experimental
    High Dose CTAP101 Capsules

    CTAP101 Capsules, 900 mcg dose

    Drug: CTAP101 Capsules

  • Experimental
    CTAP101 Injection

    IV injection, 448 mcg dose

    Drug: CTAP101 Injection

Interventions

07

What researchers measure

Primary outcomes

  1. To assess the PK and bioavailability of CTAP101 in Stage 3 and 4 CKD subjects with vitamin D insufficiency and SHPT

    Time frame: from 3 to 0 hours prior to dosing until 42 days post dosing

Secondary outcomes

  1. To assess the safety and tolerability of CTAP101 capsules and injection

    Time frame: From signing of ICF (Day -35) through study completion (Day 42 post dosing)

  2. To assess the pharmacodynamics of single dose CTAP101 in Stage 3 and Stage 4 CKD subjects with vitamin D insufficiency and SHPT.

    Time frame: From signing of ICF (Day -35) through study completion (Day 42 post dosing)

08

Study locations

12 sites
  • Pivotal Research Centers
    Peoria, Arizona 85381, United States
  • Research by Design
    Evergreen Park, Illinois 60805, United States
  • Western New England Renal & Transplant Associates
    Springfield, Massachusetts 01107, United States
  • Twin Cities Clinical Research
    Brooklyn Center, Minnesota 55430, United States
  • DCI
    Cincinnati, Ohio 45206, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109-1998, United States
  • Northeast Clinical Research
    Allentown, Pennsylvania 18103, United States
  • Southeast Renal Research Institute
    Chattanooga, Tennessee 37404, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Southwest Houston Research Ltd
    Houston, Texas 77099, United States
  • Purity Dialysis Centers / Nephrology Associates
    Delafield, Wisconsin 53018, United States
  • Gunderson Clinic Ltd.
    La Crosse, Wisconsin 54601, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Nov 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2009
First posted
Apr 24, 2009
Start
May 2009
Primary completionActual
Nov 2009
CompletionActual
Dec 2009
Last update
Sep 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00888069
Responsible party
Sponsor
First posted
Apr 24, 2009
Start date
May 2009
Primary completion
Nov 2009
Completion
Dec 2009
Last update
Sep 30, 2014

Study contacts

Joel Melnick, MD
study director · OPKO Renal

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modified-release Calcifediol Capsule

Start the discussion